Ingestion of a salty meal induces secretion of guanylin (GN)and uroguanylin (UGN) into the intestinal lumen, where theyinhibit Na+ absorption and induce Cl–, HCO3–, andwater secretion. Simultaneously, these hormones stimulate renalelectrolyte excretion by inducing natriuresis, kaliuresis, anddiuresis. GN and UGN therefore participate in the preventionof hypernatremia and hypervolemia after salty meals. The signalingpathway of GN and UGN in the intestine is well known. They activateenterocytes via guanylate cyclase C (GC-C), which leads to cGMP-dependentinhibition of Na+/H+ exchange and activation of the cystic fibrosistransmembrane regulator. In GC-C–deficient mice, GN andUGN still produce renal natriuresis, kaliuresis, and diuresis,suggesting different signaling pathways in the kidney comparedwith the intestine. Signaling pathways for GN and UGN in thekidney differ along the various nephron segments. In proximaltubule cells, a cGMP- and GC-C–dependent signaling wasdemonstrated for both peptides. In addition, UGN activates apertussis toxin–sensitive G-protein–coupled receptor.A similar dual signaling pathway is also known for atrial natriureticpeptide. Recently, a cGMP-independent signaling pathway forGN and UGN was also shown in principal cells of the human andmouse cortical collecting duct. Because GN and UGN activatedifferent signaling pathways in specific organs and even withinthe kidney, this review focuses on more recent findings on cellulareffects and signaling mechanisms of these peptides and theirpathophysiologic implications in the intestine and the kidney.
Guanylin peptides, guanylin (GN) and uroguanylin (UGN) are small,heat-stable peptides with 15 to 19 amino acids. Human GN consistsof 15 amino acids and possesses two disulfide bonds betweenthe cysteins in positions 4 to 12 and 7 to 15 (1). Human UGNconsists of 16 amino acids and also has two disulfide bondsat the same positions (2). These disulfide bonds are essentialfor the activity of the peptides. The genes for guanylin peptidesare located on the human chromosome 1 (p33 to p36) and the mousechromosome 4 (3). Human GN and UGN are coded by different butsimilar genes that consist of three exons and two introns. Bothpeptides are synthesized as prepropeptide. Guanylin peptidesare produced in the intestine after ingestion of a salty mealand secreted into the intestinal lumen (4). In the intestine,GN and UGN activate enterocytes via guanylate cyclase C (GC-C),with cGMP as second messenger (5,6). Activation of this pathwayleads to the secretion of Cl– and HCO3– and to theinhibition of Na+ absorption, which drives water secretion.In addition, these hormones induce an increased salt and waterexcretion in the kidney (7). The decrease of salt absorptionin the intestine together with the increase of renal salt excretionprevents the development of hypernatremia after ingestion ofhigh amounts of salt.
GC-C was first described as a receptor for the exogenous heat-stableenterotoxin of Escherichia coli (STa) (8). Unlike the endogenouspeptides GN and UGN, STa contains three disulfide bonds. Itis presumed that this is the reason for its stronger and uncontrolledactivation of GC-C that leads to marked intestinal secretionof electrolytes and water and is manifested as secretory diarrhea(9). The identification of a receptor for the exogenous enterotoxinin the intestine and in other tissues (kidney, reproductivesystem, and lung) led to the search for endogenous ligands forGC-C and their physiologic function. In the early 1990s, GNwas isolated from rat intestine (5) and UGN from opossum urine(6). Other recently discovered new members of this peptide familyare renoguanylin (10) and lymphoguanylin (11). Like GN and UGN,renoguanylin has two disulfide bonds, whereas lymphoguanylinpossesses only one. Lymphoguanylin is less potent than GN andUGN in the intestine (11). As guanylin peptides regulate electrolyteexcretion by the intestine and the kidney, they complement otherwell-known hormonal systems that are involved in regulationof water and electrolyte homeostasis, such as the renin-angiotensin-aldosteronesystem, adiuretin (vasopressin) or atrial natriuretic peptide(ANP), brain natriuretic peptide (BNP), and C type natriureticpeptide (CNP).
A number of excellent reviews on various aspects of guanylinpeptides exist (12,13); however, recent growing understandingof cellular signaling mechanisms also in humans is not coveredin these reviews. Therefore, the aim of this review is to summarizethe current knowledge on cellular effects of guanylin peptidesand their signaling pathways and possible pathophysiologic implicationsin different organs, mainly the intestine and the kidney ofdifferent species including man.
The big family of guanylate cyclases consists of one cytoplasmic(soluble) guanylate cyclase, which is the receptor for nitricoxide and carbonic monoxide, and six isoforms of membrane guanylatecyclases. GC-A, GC-B, and GC-C are receptors for natriureticpeptides that regulate electrolyte and water homeostasis andcontrol BP (14). GC-A (or NPR-A) is the receptor for ANP andBNP; GC-B (or NPR-B) is the receptor for CNP. A third receptorthat binds these three peptides, the so-called clearance receptor(or NPR-C), has no guanylate cyclase activity, and hormone bindingto this receptor leads to endocytosis of the hormone-receptorcomplex and activation of a pertussis toxin–sensitiveG-protein. The latter mediates an inhibition of adenylate cyclase(15,16). Guanylate cyclases D, E, and F (GC-D, GC-E, and GC-F)are expressed in sensory organs, and, until now, their agonistsand functions are not known (17–20). GC-G is also an orphanreceptor without known agonist, and it is present in skeletalmuscles, lungs, and intestine. Hirsch et al. (21) showed forthe first time the presence of GC-G also in the kidney and identifiedthis guanylate cyclase as the only membrane-bound isoform presentin principal cells of rat cortical collecting duct (CCD). Table 1summarizes the tissue distribution and known agonists forthe eight guanylate cyclases identified (22,23).
GC-C is the main receptor for guanylin peptides in the intestine(Figure 1). GC-C forms dimers, trimers, or tetramers when insertedinto the plasma membrane (24). mRNA for GC-C is present alsoin adrenal glands, brain, the embryonic or regenerating butnot adult liver, placenta, testis, airways, spleen, thymus,and lymphatic nodes (25–27). Human and rat GC-C have 71%homology in the extracellular domain and 91% in the intracellulardomain. The extracellular domain must be glycosylated for completereceptor activity (28,29), and dephosphorylation caused by bindingof an agonist to the extracellular domain leads to loss of receptorsensitivity (30).
Figure 1. Guanylate cyclase C (GC-C) forming a dimer. The binding of guanylin (GN), uroguanylin (UGN), or heat-stable enterotoxin of Escherichia coli (STa) to the extracellular domain of GC-C leads to activation of the catalytic domain with the production of cGMP and the dephosphorylation of the kinase homology domain with receptor desensitization. For details, see text. L, ligand.
The most studied regulator of GC-C activity is protein kinaseC (PKC). GC-C phosphorylation by PKC leads to an increase incGMP accumulation. PKC-induced phosphorylation at the C-terminaltail increased STa-mediated cGMP generation by 70% when comparedwith the nonphosphorylated receptor (31,32).
The existence of additional receptors for guanylin peptidesbecame evident when, for example, intestinal and renal effectsof these peptides were examined in GC-C–deficient mice.These mice are resistant to intestinal secretion produced bySTa (33–35), but approximately 10% of the intestinal bindingsites for these peptides are still present when compared withwild-type mice. In the kidney, guanylin peptides still inducesaluresis and diuresis in these GC-C–deficient mice (36),strongly suggesting an additional receptor and possibly signalingcascade for guanylin peptides at least in the kidney and tosome extent also in the intestine. That renal effects of guanylinpeptides are maintained when GC-C is absent also indicates thatGC-C plays no or only a minor role for these peptides in thekidney.
Signaling Pathways of Guanylin Peptides in the Intestine
Guanylin peptides secreted into the intestinal lumen in responseto high oral salt intake bind to GC-C localized in the luminalmembrane of enterocytes and induce electrolyte and water excretionby a complex signaling cascade (Figure 2):
Increase of the intracellularconcentration of cGMP (5,6,8)
Inhibition of Na+/H+ exchange,which results in decreased Na+reabsorption (37)
Activation of PKA directly (40,41) or indirectlyvia inhibitionof phosphodiesterase III (PDE III), which leadsto an increaseof cellular cAMP and activation of PKA (39)
PKGII and PKA activate cystic fibrosis transmembrane regulator(CFTR) in the luminal membrane (42), leading to Cl– secretioninto the intestinal lumen
CFTR activates the Cl–/HCO3–exchanger, which leadsto bicarbonate secretion into the intestinallumen (43)
Figure 2. Signaling pathway of guanylin peptides in the intestine. GN, UGN, and STa activate membrane-bound GC-C, which increases the intracellular concentration of cGMP. cGMP inhibits the Na+/H+ exchanger (NHE) and activates protein kinase G type II (PKG II) and protein kinase A (PKA). Both protein kinases activate Cl– and HCO3– secretion via activation of cystic fibrosis transmembrane regulator (CFTR) followed by an activation of the Cl–/HCO3– exchanger. Depicted is a schematic drawing of an enterocyte including the major components necessary for electrolyte transport. PDE III, phosphodiesterase type III (inhibited by cGMP). Illustration by Josh Gramling—Gramling Medical Illustration.
GN and UGN are expressed along the intestinal tract (Figure 3)together with GC-C (44–46), which is the major intestinalreceptor for GN and UGN. However, the expression pattern ofthese two hormones is differential, i.e., highest expressionof UGN in the jejunum and highest expression of GN in ileumto proximal colon. The distal colon expresses only small amountsof both hormones.
Figure 3. Relative expression of GN () and UGN () mRNA along the intestinal tract. Adapted from reference (46).
As indicated above, a few studies show the existence of a signalingpathway at least for STa distinct of GC-C (33–35). Furthermore,binding sites for guanylin peptides that are distinct from GC-Care also located on the basolateral membrane of colonocytes(47). STa also activates the Ca2+ signaling pathway with activationof PKC (48,49), which could be independent of GC-C activation.
The effects of GN and UGN on cellular cGMP via GC-C depend onextracellular pH. UGN is more potent at pH 5 compared with pH8. Conversely, GN is more potent at pH 8 compared with pH 5(Figure 4). As this pH dependence affects the ligand/receptorinteraction, it was suggested that the N-terminal ends of theUGN and GN molecules are responsible for this pH dependence(50). The duodenum secretes bicarbonate to neutralize the acidicpH of the stomach contents that enter the duodenum. This acid-stimulatedduodenal mucosal bicarbonate secretion is cGMP dependent. UGNregulates the luminal pH in the duodenum by activation of bicarbonatesecretion and inhibition of H+ secretion because unlike GN,UGN is localized predominantly in the proximal part of intestinaltract (Figure 3). This effect is enhanced as UGN has higheractivity at acidic pH and leads to stronger HCO3– secretioninto duodenal lumen.
Figure 4. GN and UGN increase the cellular concentration of cGMP pH-dependently. GN is more potent at pH 8.0, and UGN is more potent at pH 5.0. Adapted from reference (50).
Signaling Mechanisms of Guanylin Peptides in the Kidney
Guanylin peptides increase the secretion of Na+, K+, and waterin the kidney without changes in GFR or renal blood flow (7,36).UGN is proposed to be an intestinal natriuretic peptide, asnatriuresis produced by oral salt load is decreased in UGN-deficientmice (51). Thus, the action of UGN in the kidney can be endocrine(produced in the intestine with actions in the kidney), paracrine(produced by the kidney), or both. Kinoshita et al. (52) showedhigher UGN concentration in blood and urine of individuals whowere on a high-salt diet compared with those who were on a low-saltdiet, which speaks in favor of an endocrine function of UGN.Recently, Fukae et al. (53) showed that rats that are fed ahigh-salt diet have higher UGN and cGMP concentrations in theurine but show no changes in the concentration of UGN in theplasma compared with control animals. UGN is expressed in thekidney, and its expression is higher in animals that are ona high-salt diet (53,54). It is still not clear whether theincrease in the urinary concentrations of UGN and cGMP (52,53)are due to local production and secretion of UGN within thekidney or to filtration in the glomerulus.
Both GN and UGN circulate in the plasma and can be filteredin the glomerulus into the primary urine. UGN is excreted viathe final urine, whereas hardly any GN can be found in the urine(6,55). A possible reason that GN is not present in the finalurine is its sensitivity to chymotrypsin, which quickly degradesGN after glomerular filtration or secretion of GN into the tubularlumen (9,56). These differences in the degradation and expressionpattern of GN and UGN suggest that GN probably acts strictlyautocrine, whereas UGN has paracrine activity in the kidney.The concentration of UGN in the urine correlates with that ofurinary cGMP, which again supports the hypothesis that cGMPand the GC-C signaling pathways are activated by UGN at leastin the cells of the proximal tubule. However, another possiblesource of cGMP in the urine could be the activation of othermembers of the guanylate cyclase family, such as the orphanreceptor GC-G, which is present in the luminal membrane of principalcells of rat and mouse CCD (21,57). The source of guanylin peptidesin the tubular lumen besides glomerular filtration from thecirculation could also be tubular cells because mRNA for GNand UGN is also expressed in kidney epithelial cells (54,58,59).Similar to the difference in the axial expression along theintestine, GN and UGN are not expressed equally along the differentnephron segments (Figure 5). UGN is present mostly in the proximaltubule, again comparable to the proximal intestine, and GN ismore pronounced in the collecting duct, in analogy to GN expressionin the colon.
Figure 5. Relative mRNA expression of GN (A) and UGN (B) in various mouse nephron segments. GL, glomerulus; PT, proximal tubule; TAL, thick ascending limb of Henle’s loop; CD, collecting duct; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Mean values ± SEM, n = 4. Adapted from reference (54).
Markedly different from the expression along the entire intestinaltract, GC-C, the first receptor for guanylin peptides identified,is not present in all nephron segments. Potthast et al. (54)localized GC-C in the mouse kidney only in glomeruli and proximaltubules. In the human kidney, we detected GC-C again only inthe kidney cortex and specifically in proximal tubules (Figure 6)(60,61). In contrary to these findings in mouse and human,in rat kidney, Carrithers et al. (58) found mRNA for GC-C inall nephron segments, suggesting differences in tissue distributionof GC-C in different species. A few years ago, it became evidentthat proximal tubules are targets of guanylin peptides. Guanylinpeptides increase the intracellular cGMP concentration in aproximal tubule cell line of opossum kidney (OK cells) via theopossum kidney GC-C (OK-GC), which is the analog to the humanGC-C (62). Recently, we demonstrated an increase in the cellularcGMP concentration induced by guanylin peptides also in a humanproximal tubule cell line (IHKE1) (61). In this cell line, GNand UGN also activated GC-C.
Figure 6. Expression of mRNA for GC-C in human nephron segments. G, glomeruli; CCD, cortical collecting ducts; M, marker; (–), negative control (no cDNA); (+), positive control. Adapted from reference (60).
The intestinal pH dependence for the binding of GN and UGN toGC-C (see above) probably also is relevant in the kidney. Inthe human proximal tubule cell line, UGN activated GC-C at pH5 more pronounced than at pH 8 (Figure 4). At alkaline pH, whenUGN effects on GC-C in these proximal tubular cells were lower,an additional signaling pathway via pertussis toxin–sensitiveG-proteins was revealed (61). Therefore, tubular pH can playan important role in activating GN versus UGN signaling pathwaysand activating different signaling pathways for UGN (Figure 7).This might be even more relevant along the medullary collectingduct, where tubular pH can be significantly acidic. Data oneffects of guanylin peptides along this nephron segment, however,are still completely missing.
Figure 7. pH dependence of effects of guanylin peptides on membrane voltages of human proximal tubule cells. At pH 5.5, UGN activated GC-C and depolarized cells; at pH 8.0, it activated a G-protein–coupled receptor and hyperpolarized the cells. GN and STa depolarize cells only via activation of the GC-C–dependent signaling pathway. Mean values ± SEM, n given in brackets. Adapted from reference (61).
Data from various proximal tubule cells in culture suggest thatguanylin peptides inhibit Na+ reabsorption in this nephron segment.UGN decreases the expression of the Na+/K+-ATPase, which wouldlower the concentration gradient for Na+ and therefore reduceNa+-coupled electrolyte and substrate reabsorption from thetubular lumen (63). According to our own observations in thehuman proximal tubule cell line, GN and UGN decrease the electricaldriving force for Na+ reabsorption by inhibiting K+ channelsvia cGMP and depolarizing cells (61). Finally, the increasein cellular cGMP by GN and UGN should, like in the intestine(37), inhibit luminal Na+/H+ exchange and thereby reduce Na+and volume reabsorption. Indeed, in the human proximal tubulecell line, UGN inhibited Na+/H+ exchange activity (SchlatterE., unpublished results). As mentioned above, guanylin peptidesstill cause natriuresis, kaliuresis, and diuresis in GC-C–deficientmice, suggesting a second receptor in the kidney for these peptides(36). In addition to this GC-C–and cGMP-dependent signalingpathway, UGN can activate a pertussis toxin–sensitiveG-protein that leads to activation of a K+ conductance (61).Which signaling pathway will be activated by UGN could dependon luminal pH (Figure 7). Figure 8 shows a summary of actionsof guanylin peptides on proximal tubular cells on ion and watertransport. The molecular identity of this second receptor, thephysiologic role of this cGMP-independent signaling pathway,and the relative contributions of these two signaling pathwaysremains to be elucidated.
Figure 8. Signaling pathways of guanylin peptides in renal proximal tubule cells. Guanylin peptides activate two signaling pathways. One is GC-C and cGMP dependent. cGMP decreases Na+ reabsorption by inhibiting different proteins in the membrane: K+ channels, Na+/H+ exchanger, and Na+/K+-ATPase. The other signaling pathway involves activation of a pertussis toxin–sensitive G-protein. AQP1, aquaporin 1; NBC, Na+/HCO3– co-transporter; NHE3, Na+/H+ exchanger; OK-GC, guanylate cyclase from opossum kidney. Illustration by Josh Gramling—Gramling Medical Illustration.
The presence of two receptors for one peptide even at the samecell is known for other hormones that also act in the kidney.ANP activates two different types of receptors (64); one isGC-A, and, like GC-C, its activation leads to the productionof cGMP (65). The other receptor is the natriuretic peptidereceptor type C, or clearance receptor (NPR-C), which is a pertussistoxin–sensitive G-protein–coupled receptor (15,16).It remains to be clarified whether the G-protein–coupledreceptors for UGN and ANP are the same or similar.
Fine regulation of renal electrolyte and water excretion takesplace in the collecting duct. Principal cells of the CCD areresponsible for K+ secretion (via K+ channels [ROMK]), Na+ reabsorption(via epithelial Na+ channels [ENaC]), and water reabsorption(via aquaporins 2, 3, and 4). In line with the observation thatGC-C–deficient mice still exert natriuresis, kaliuresis,and diuresis upon infusion of guanylin peptides (36) is theabsence of mRNA for GC-C in CCD of mouse and man (54,60). However,guanylin peptides induce changes in membrane voltages of principalcells of mouse and human CCD both in wild-type and in GC-C–deficientmice, suggesting modification of electrogenic ion transportalso in this nephron segment (57,60). Similar to the situationin the human proximal tubule cell line, in principal cells ofisolated mouse and human CCD segments, guanylin peptides activatea signaling pathway distinct from GC-C and independent of cGMP.Guanylin peptides depolarize these cells, whereas the membrane-permeableanalog of cGMP, 8Br-cGMP, hyperpolarizes the same cells, excludingcGMP as a possible second messenger in this signaling pathwayfor guanylin peptides in these cells (60). This pathway of GNand UGN in the CCD involves again a G-protein–coupledreceptor, like in the proximal tubule cell line. Activationof this receptor leads to stimulation of phospholipase A2 (PLA2)and liberation of arachidonic acid. It has been reported beforethat arachidonic acid inhibits the secretory ROMK channels locatedat the luminal membrane of principal cells (66). Inhibitionof the secretory K+ channels by guanylin peptides thereforedecreases K+ secretion and lowers the electrical driving forcefor Na+ reabsorption that results in natriuresis. In mouse principalcells of the CCD, apparently in addition to this cGMP-independentsignaling pathway, another pathway for guanylin peptides exists.This pathway is cGMP dependent but GC-C independent (57). Thereceptor that is activated by guanylin peptides in the mouseCCD and leads to cGMP and PKG activation is still not identified.A possible candidate for this receptor is the orphan receptorguanylate cyclase G (21,57). Activation of this pathway resultsin activation of cGMP-dependent K+ channels in the basolateralmembrane of principal cells and cell hyperpolarization.
Figure 9 shows a model of a principal cell of the CCD indicatingall mechanisms of actions of guanylin peptides identified sofar. It is evident from this scheme that the guanylin peptidesare the first peptides identified that act in this nephron segmentprimarily on K+ channels without directly affecting Na+ channels.In the human CCD, the depolarization of principal cells viainhibition of the secretory K+ channels results in natriuresisas the predominant effect observed in vivo with these peptides(7,36,67). Reduced Na+ reabsorption also decreases water reabsorptionin this nephron segment and thus causes diuresis. GN was shownto decrease the cell volume and increase the luminal space ina concentration- and time-dependent manner, which suggests secretionof water and consequently diuresis (68). However, the kaliuresisalso caused by guanylin peptides cannot be explained from thedata obtained in the CCD and may be due to effects of thesepeptides in other parts of the nephron, e.g., the thick ascendinglimb or the medullary collecting duct. Again, the physiologicrole of the second cGMP-dependent signaling pathway and therelative contributions of these two signaling pathways in theCCD of the mouse remains to be elucidated. This second pathwayinvolves an activation of basolateral K+ channels and therebyshould increase Na+ reabsorption without an increase in K+ secretion.
Figure 9. Signaling pathways of GN and UGN in a principal cell of the CCD. Guanylin peptides activate phospholipase A2 (PLA2), which leads to an increase in the intracellular concentration of arachidonic acid and an inhibition of luminal ROMK K+ channels. ENaC, epithelial sodium channels; AQP 2, 3, 4, aquaporins 2, 3, and 4; NKA, Na+/K+ ATPase. Illustration by Josh Gramling—Gramling Medical Illustration.
Cellular Effects of Guanylin Peptides in Other Organs
Patients with cystic fibrosis undergo changes in water and electrolytesecretion in the liver, the pancreas, the lung, and the intestine.Thus, it might be speculated whether guanylin peptides are alsoinvolved in the regulation of electrolyte and water secretionin those organs via CFTR. Guanylin peptides and parts of theirsignaling pathway are present in the pancreas. John et al. (69)showed that GN and STa increase intracellular cGMP via GC-Cin a human pancreatic cell line. Kulaksiz et al. (70,71) detectedmRNA for GC-C and UGN in cells of the exocrine part of the pancreas,and guanylin peptides increase cGMP, which leads to activationof CFTR in these cells.
Guanylin peptides and parts of the GC-C–dependent signalingpathway are also found in airways (26,27), sweat glands, theadrenal medulla, and the male reproductive system (72–74).According to this limited information on effects of guanylinpeptides in various organs, the GC-C–dependent signalingpathway seems to be the predominant signaling pathway in mostorgans and only in the kidney does the signaling involve differentreceptors and signaling mechanisms.
Exiting observations are the involvement of guanylin peptidesin the development and possible treatment of intestinal tumors.GN and UGN are less expressed or they are not present at allin colon adenocarcinoma, adenoma, and intestine polyps in humanand mouse (75–77). The gene for GN is located at 1 p34–35,which is a tumor-modifying region. One can presume that lossof GN activity leads to or is the result of tumor development.Pitari et al. (78) hypothesized that the reason for the lowerincidence of intestinal tumors in third-world countries is thehigher incidence of intestinal infections that stimulate intestinalGC-C and lead to an increase in cGMP. Guanylin peptides andalso STa in addition regulate proliferation and differentiation,prolonging the cell cycle, and induce apoptosis of T84, CaCo2cells, and mouse intestinal cells (78–81). Shailubahaiet al. (77) showed that oral application of UGN leads to andecrease in number and size of polyps in mice that develop intestinalpolyposis, which allows us to speculate on the possible usageof UGN in the treatment of intestinal tumors.
The involvement of guanylin peptides was suggested also in differentkidney diseases. More than 11 yr ago, Nakazato et al. (82) showedthat human GN increases in patients who have chronic renal failureand undergo hemodialysis. The UGN concentration in plasma and/orin urine is increased in patients with chronic renal failureand glomerulonephritis and in patients on hemodialysis (52,83–85).In patients with nephrotic syndrome, UGN plasma concentrationwas higher and urinary concentration was lower compared withvalues in healthy volunteers (84). Possible explanations forthese observations are kidney damages and reduced capabilityto metabolize and excrete guanylin peptides. Recently, Kikuchiet al. (86) suggested that UGN plays a role as a natriureticfactor in nephrotic syndrome. In experimental nephrotic syndrome,induced by intraperitoneal injection of puromycin aminonucleoside(PAN), changes in UGN concentrations in urine and plasma correspondedto changes in Na+ excretion. In the same animals, the expressionof mRNA for UGN changed in the kidney but not in the intestine,and it was not seen in control animals.
In contrast to other natriuretic peptides, like ANP, the connectionbetween guanylin peptides and hypertension is not well understood.UGN-deficient mice have increased mean arterial pressure, whichis salt insensitive (51). However, GC-C–deficient miceshow no difference in BP compared with wild-type mice (33,34),which rules out a significant involvement of GC-C in the regulationof BP. As shown in this review, guanylin peptides activate atleast one cGMP-, GC-C–independent signaling pathway. Liberationof arachidonic acid in the renal collecting duct by guanylinpeptides inhibits the secretory ROMK channels, which lowersthe electrical driving force for Na+ reabsorption, resultingin natriuresis. In UGN-deficient mice, UGN cannot activate thissignaling pathway, which will lead to higher reabsorption ofNa+ and possibly induce hypertension (51).
GN and UGN regulate electrolyte and water transport in the intestineand cause kaliuresis, natriuresis, and diuresis in the kidney.The membrane-bound GC-C is the receptor for these peptides inthe intestine. In the kidney, these peptides activate differentsignaling pathways along the nephron. Although GC-C is the predominantreceptor mediating the effects of guanylin peptides in the intestine,it plays only a minor role in the kidney, probably restrictedto the proximal tubule. Whereas in the intestine the signalingpathway of guanylin peptides is singular, in the kidney, atleast three different receptors with different second messengersystems are activated and mediate complex effects on electrolyteand water excretion. The molecular identity of these renal receptorsfor guanylin peptides remains to be determined. First indicationsof an involvement of these peptides in various diseases indicatealso a pathophysiologic role and possibly a therapeutic valueof these peptides.
Acknowledgments
The data of the authors laboratory cited and presented in thisreview were funded by a grant of the Medical Faculty of theUniversity of Münster (IMF, KU 21 98 09) and by grantsof the Deutsche Forschungsgemeinschaft (Schl 277/11-1 to 11-3).
Footnotes
Published online ahead of print. Publication date availableat www.jasn.org.
de Sauvage FJ, Keshav S, Kuang WJ, Gillett N, Henzel W, Goeddel DV: Precursor, structure, expression, and tissue distribution of human guanylin.
Proc Natl Acad Sci U S A 89
: 9089
–9093, 1992[Abstract/Free Full Text]
Kita T, Smith CE, Fok KF, Duffin KL, Moore WM, Karabatsos PJ, Kachur JF, Hamra FK, Pidhorodeckyj NV, Forte LR, Currie MG: Characterization of human uroguanylin: A member of the guanylin peptide family.
Am J Physiol Renal Physiol 266
: F342
–F348, 1994[Abstract/Free Full Text]
Schulz S: Targeted gene disruption in the development of mouse models to elucidate the role of receptor guanylyl cyclase signaling pathways in physiological function.
Methods 19
: 551
–558, 1999[CrossRef][Medline]
Kita T, Kitamura K, Sakata J, Eto T: Marked increase of guanylin secretion in response to salt loading in the rat small intestine.
Am J Physiol 277
: G960
–G966, 1999[Medline]
Currie MG, Fok KF, Kato J, Morre RJ, Hamra FK, Duffin KL, Smith CE: Guanylin: An endogenous activator of intestinal guanylate cyclase.
Proc Natl Acad Sci U S A 89
: 947
–951, 1992[Abstract/Free Full Text]
Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, Chin DT, Tompkins JA, Fok KF, Smith CE, Duffin KL, Siegel NR, Currie MG: Uroguanylin: Structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase.
Proc Natl Acad Sci U S A 90
: 10464
–10468, 1993[Abstract/Free Full Text]
Fonteles MC, Greenberg RN, Monteiro HSA, Currie MG, Forte LR: Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney.
Am J Physiol Renal Physiol 275
: F191
–F197, 1998[Abstract/Free Full Text]
Schulz S, Green KC, Yuen PST, Garbers DL: Guanylyl cyclase is a heat-stable enterotoxin receptor.
Cell 63
: 941
–948, 1990[CrossRef][Medline]
Carpick BW, Gariepy J: The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin.
Infect Immun 61
: 4710
–4715, 1993[Abstract/Free Full Text]
Yuge S, Inoue K, Hyodo S, Takei Y: A novel guanylin family (guanylin, uroguanylin, and renoguanylin) in eels: Possible osmoregulatory hormones in intestine and kidney.
J Biol Chem 278
: 22726
–22733, 2003[Abstract/Free Full Text]
Forte LR, Eber SL, Fan X, London RM, Wang Y, Roland L, Chin DT, Freeman RH, Krause WJ: Lymphoguanylin: Cloning and characterization of a unique member of the guanylin peptide family.
Endocrinology 140
: 1800
–1806, 1990
Forte LR: Uroguanylin and guanylin peptides: Pharmacology and experimental therapeutics.
Pharmacol Ther 104
: 137
–162, 2004[CrossRef][Medline]
Vaandrager AB: Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C.
Mol Cell Biochem 230
: 73
–83, 2002[CrossRef][Medline]
Kuhn M: Molecular physiology of natriuretic peptide signaling.
Basic Res Cardiol 99
: 76
–82, 2004[CrossRef][Medline]
Anand-Srivastava MB, Sehl PD, Lowe DG: Cytoplasmatic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase: Involvement of a pertussis toxin-sensitive G protein.
J Biol Chem 271
: 19324
–19329, 1996[Abstract/Free Full Text]
Murthy KS, Teng BQ, Zhou H, Jin JG, Grider JR, Makhlouf GM: Gi-1/Gi-2-dependent signaling by single-transmembrane natriuretic peptide clearance receptor.
Am J Physiol 278
: G974
–G980, 2000
Seebacher T, Beitz E, Kumagami H, Wild K, Ruppersberg JP, Schultz JE: Expression of membrane-bound and cytosolic guanylyl cyclase in the rat inner ear.
Hearing Res 127
: 95
–102, 1999[CrossRef][Medline]
Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, Beavo JA: The subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase D define a unique olfactory signal transduction pathway.
Proc Natl Acad Sci U S A 94
: 3388
–3395, 1997[Abstract/Free Full Text]
Fülle HJ, Vassar R, Foster DC, Yang RB, Axel R, Garbers DL: A receptor guanylyl cyclase expressed specifically in olfactory sensory neurons.
Proc Natl Acad Sci U S A 92
: 3571
–3575, 1995[Abstract/Free Full Text]
Yang RB, Foster DC, Garbers DL, Fulle H-J: Two membrane forms of guanylyl cyclase found in the eye.
Proc Natl Acad Sci U S A 92
: 602
–606, 1995[Abstract/Free Full Text]
Hirsch JR, Kruhoffer M, Herter P, Adermann K, Heitland A, Meyer M, Forssmann WG, Plenz G, Schlatter E: Cellular localization, membrane distribution and possible function of guanylyl cyclase A and 1 in collecting duct of rat.
Cardiovasc Res 51
: 553
–561, 2001[Abstract/Free Full Text]
Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA: Guanylyl cyclases and signaling by cyclic GMP.
Pharmacol Rev 52
: 375
–414, 2000[Abstract/Free Full Text]
Vijayachandra K, Guruprasad M, Bhandari R, Manjunath UH, Somesh BP, Srinivasan N, Suguna K, Visweswariah SS: Biochemical characterization of the intracellular domain of the human guanylyl cyclase C receptor provides evidence for a catalytically active homotrimer.
Biochemistry 39
: 16075
–16083, 2000[CrossRef][Medline]
Fan X, Wang Y, London RM, Eber SL, Krause WJ, Freeman RH, Forte LR: Signaling pathways for guanylin and uroguanylin in the digestive, renal, central nervous, reproductive, and lymphoid systems.
Endocrinology 138
: 4636
–4648, 1997[Abstract/Free Full Text]
Range SP, Holland ED, Basten GP, Knox AJ: Regulation of guanosine 3',5'-cyclic monophosphate in ovine tracheal epithelial cells.
Br J Pharmacol 120
: 1249
–1254, 1997[CrossRef]
Schulz S, Chrisman TD, Garbers DL: Cloning and expression of guanylin its existence in various mammalian tissues.
J Biol Chem 267
: 16019
–16021, 1992[Abstract/Free Full Text]
Vaandrager AB, Schulz S, de Jonge HR, Garbers DL: Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine.
J Biol Chem 268
: 2174
–2179, 1993[Abstract/Free Full Text]
Hasegawa M, Hidika Y, Wada A, Hirayama T, Shimonishi Y: The relevance of N-linked glycosylation to the binding of a ligand to guanylate cyclase C.
Eur J Biochem 263
: 338
–345, 1999[Medline]
Potter LR, Garbers DL: Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization.
J Biol Chem 267
: 14531
–14534, 1992[Abstract/Free Full Text]
Wada A, Hasegawa M, Matsumoto K, Niidome T, Kawano Y, Hidaka Y, Padilla PI, Kurazono H, Shimonishi Y, Hirayama T: The significance of Ser1029 of the heat-stable enterotoxin receptor (STaR): Relation of STa-mediated guanylyl cyclase activation and signaling by phorbol myristate acetate.
FEBS Lett 384
: 75
–77, 1996[CrossRef][Medline]
Crane JK, Wehner MS, Bolen EJ, Sando JJ, Linden J, Guerrant RL, Sears CL: Regulation of intestinal guanylate cyclase by the heat-stable enterotoxin of
Escherichia coli (STa) and protein kinase C. Infect Immun 60
: 5004
–5012, 1992
Mann EA, Jump ML, Wu J, Yee E, Giannella RA: Mice lacking the guanylyl cyclase C receptor are resistant to STa-induced intestinal secretion.
Biochem Biophys Res Commun 239
: 463
–466, 1997[CrossRef][Medline]
Schulz S, Lopez MJ, Kuhn M, Garbers DL: Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice.
J Clin Invest 100
: 1590
–1595, 1997[Medline]
Charney AN, Egnor RW, Alexander-Chacko JT, Zaharia V, Mann EA, Giannella RA: Effect of
E. coli heat-stable enterotoxin on colonic transport in guanylyl cyclase C receptor-deficient mice. Am J Physiol 280
: G216
–G221, 2001
Carrithers SL, Ott CE, Hill MJ, Johnson BR, Cai W, Chang JJ, Shah RG, Sun C, Mann EA, Fonteles MC, Forte LR, Jackson BA, Giannella RA, Greenberg RN: Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor.
Kidney Int 65
: 40
–53, 2004[CrossRef][Medline]
Fawcus K, Gorrton VJ, Lucas ML, McEwan GTA: Stimulation of three distinct guanylate cyclases induces mucosal surface alkalinisation in rat small intestine in vitro.
Comp Biochem Physiol A Physiol 118
: 291
–295, 1997[Medline]
Vaandrager AB, Bot AGM, de Jonge HR: Guanosine 3',5'-cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine.
Gastroenterology 112
: 437
–443, 1997[CrossRef][Medline]
Vaandrager AB, Bot AGM, Ruth P, Pfeifer A, Hofmann F, de Jonge HR: Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon.
Gastroenterology 118
: 108
–114, 2000[CrossRef][Medline]
Forte LR, Thorne PK, Eber SL, Krause WJ, Freeman MJ, Francis SH, Corbin JD: Stimulation of intestinal Cl– transport by heat-stable enterotoxin: Activation of cAMP-dependent protein kinase by cGMP.
Am J Physiol 263
: C607
–C615, 1992[Medline]
Chao AC, de Sauvage FJ, Dong YJ, Wagner JA, Goeddel DV, Gardner P: Activation of intestinal CFTR Cl– channel by heat-stable enterotoxin and guanylin via cAMP-dependent protein kinase.
EMBO J 13
: 1065
–1072, 1994[Medline]
Crawford I, Maloney PC, Zeitlin PL, Guggino WB, Hyde SC, Turley H, Gatter KC, Harris A, Higgins CF: Immunocytochemical localization of the cystic fibrosis gene product CFTR.
Proc Natl Acad Sci U S A 88
: 9262
–9266, 1991[Abstract/Free Full Text]
Ko SB, Zeng W, Dorwart MR, Luo X, Kim KH, Millen L, Goto H, Naruse S, Soyombo A, Thomas PJ, Muallem S: Gating of CFTR by the STAS domain of SLC26 transporters.
Nat Cell Biol 6
: 343
–350, 2004[CrossRef][Medline]
Nandi A, Bhandari R, Visweswariah SS: Epitope conservation and immunohistochemical localization of the guanylin/stable toxin peptide receptor, guanylyl cyclase C.
J Cell Biochem 66
: 500
–511, 1997[CrossRef][Medline]
Qian X, Prabhakar S, Nandi A, Visweswariah SS, Goy MF: Expression of GC-C, a receptor-guanylate cyclase, and its endogenous ligands uroguanylin and guanylin along the rostrocaudal axis of the intestine.
Endocrinology 141
: 3210
–3224, 2000[Abstract/Free Full Text]
Whitaker TL, Witte DP, Scott MC, Cohen MB: Uroguanylin and guanylin: Distinct but overlapping patterns of messenger RNA expression in mouse intestine.
Gastroenterology 113
: 1000
–1006, 1997[CrossRef][Medline]
Albano F, Brasitus T, Mann EA, Guarino A, Giannella RA: Colonocyte basolateral membranes contain
E. coli heat-stable enterotoxin receptors. Bichem Biophys Res Commun 284
: 331
–334, 2001
Ganguly U, Chaudhury AG, Basu A, Sen PC: STa-induced translocation of protein kinase C from cytosol to membrane in rat enterocytes.
FEMS Microbiol Lett 204
: 65
–69, 2001[CrossRef][Medline]
Weikel CS, Spann CL, Chambers CP, Crane JK, Linden J, Hewlett EL: Phorbol esters enhance the cyclic GMP response of T84 cells to the heat-stable enterotoxin of
Escherichia coli (STa). Infect Immun 58
: 1402
–1407, 1990
Hamra FK, Eber SL, Chin DT, Currie MG, Forte LR: Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity.
Proc Natl Acad Sci U S A 94
: 2705
–2710, 1997[Abstract/Free Full Text]
Lorenz JN, Nieman M, Sabo J, Sanford P, Hawkins JA, Elitsur N, Gawenis LR, Clarke LL, Cohen MB: Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral NaCl load.
J Clin Invest 122
: 1244
–1254, 2003
Kinoshita H, Fujimoto S, Nakazato M, Yokota N, Date Y, Yamaguchi H, Hisanaga S, Eto T: Urine and plasma levels of uroguanylin and its molecular form in renal diseases.
Kidney Int 52
: 1028
–1034, 1997[Medline]
Fukae H, Kinoshita H, Fujimoto S, Kita T, Nakazato M, Eto T: Changes in urinary levels and renal expression of uroguanylin on low or high salt diets in rats.
Nephron 92
: 373
–378, 2002[CrossRef][Medline]
Potthast R, Ehler E, Scheving LA, Sindic A, Schlatter E, Kuhn M: High salt intake increases uroguanylin expression in mouse kidney.
Endocrinology 142
: 3087
–3097, 2001[Abstract/Free Full Text]
Fan X, Hamra FK, London RM, Eber SL, Krause WJ, Freeman RH, Smith CE, Currie MG, Forte LR: Structure and activity of uroguanylin and guanylin from the intestine and urine of rats.
Am J Physiol 273
: E957
–E964, 1997[Medline]
Hamra FK, Fan X, Krause WJ, Freeman RH, Chin DT, Smith CE, Currie MG, Forte LR: Prouroguanylin and proguanylin: Purification from colon, structure, and modulation of bioactivity by proteases.
Endocrinology 137
: 257
–265, 1996[Abstract]
Sindic A, Velic A, Basoglu C, Hirsch JR, Edemir B, Kuhn M, Schlatter E: Uroguanylin and guanylin regulate transport of mouse cortical collecting duct independent of guanylate cyclase C.
Kidney Int 68
: 1008
–1017, 2005[CrossRef][Medline]
Carrithers SL, Taylor B, Cai WY, Johnson BR, Ott CE, Greenberg RN, Jackson BA: Guanylyl cyclase-C receptor mRNA distribution along the rat nephron.
Regul Pept 95
: 65
–74, 2000[CrossRef][Medline]
Fujimoto S, Kinoshita H, Hara S, Nakazato M, Hisanaga S, Eto T: Immunohistochemical localization of uroguanylin in the human kidney.
Nephron 84
: 88
–89, 2000[CrossRef][Medline]
Sindic A, Hirsch JR, Velic A, Piechota H, Schlatter E: Guanylin and uroguanylin regulate electrolyte transport in isolated human cortical collecting ducts.
Kidney Int 67
: 1420
–1427, 2005[CrossRef][Medline]
Sindic A, Basoglu C, Cerci A, Hirsch JR, Potthast R, Kuhn M, Ghanekar Y, Visweswariah SS, Schlatter E: Guanylin, uroguanylin and STa activate guanylate cyclase C and/or a PT-sensitive G protein in human proximal tubule cells.
J Biol Chem 277
: 17758
–17764, 2002[Abstract/Free Full Text]
London RM, Eber SL, Visweswariah SS, Krause WJ, Forte LR: Structure and activity of OK-GC: A kidney receptor guanylate cyclase activated by guanylin peptides.
Am J Physiol 276
: F882
–F891, 1999[Medline]
Carrithers SL, Hill MJ, Johnson BR, O’Hara SM, Jackson BA, Ott CE, Lorenz J, Mann EA, Giannella RA, Forte LR, Greenberg RN: Renal effects of uroguanylin and guanylin in vivo.
Braz J Med Biol Res 32
: 1337
–1344, 1999[Medline]
Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA: Physiological role of silent receptors of atrial natriuretic factor.
Science 238
: 675
–678, 1987[Abstract/Free Full Text]
Waldman SA, Rapoport RM, Murad F: Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues.
J Biol Chem 259
: 14332
–14334, 1984[Abstract/Free Full Text]
Macica CM, Yang Y, Hebert SC, Wang WH: Arachidonic acid inhibits activity of cloned renal K+ channel, ROMK1.
Am J Physiol Renal Physiol 271
: F588
–F594, 1996[Abstract/Free Full Text]
Greenberg RN, Hill MJ, Crytzer J, Krause WJ, Eber SL, Hamra FK, Forte LR: Comparison of effects of uroguanylin, guanylin and
Escherichia coli heat-stable enterotoxin STa in mouse intestine and kidney: Evidence that uroguanylin is an intestinal natriuretic hormone. J Invest Med 45
: 276
–283, 1997
Furuya S, Naruse S, Ando E, Nikohara K, Hayakawa T: Effect and distribution of intravenously injected 125I-guanylin an rat kidney examined by high-resolution light microscopic radioautography.
Anat Embryol 196
: 185
–193, 1997[CrossRef][Medline]
John M, Wiedenmann B, Hruhoffer M, Adermann K, Ankorina-Stark I, Schlatter E, Ahnert-Hilger G, Forssmann WG, Kuhn M: Guanylin stimulates regulated secretion from human neuroendocrine pancreatic cells.
Gastroenterology 114
: 791
–797, 1998[CrossRef][Medline]
Kulaksiz H, Schmid A, Honscheid M, Eissele R, Klempnauer J, Cetin Y: Guanylin in the human pancreas: A novel luminocrine regulatory pathway of electrolyte secretion via cGMP and CFTR in the ductal system.
Histochem Cell Biol 115
: 131
–145, 2001[CrossRef][Medline]
Kulaksiz H, Cetin Y: Uroguanylin and guanylate cyclase C in the human pancreas: Expression and mutuality of ligand/receptor localization as indicators of intracellular paracrine signaling pathways.
J Endocrinol 170
: 267
–275, 2001[Abstract]
Spreca A, Simonetti S, Rambotti MG: Atrial natriuretic peptide and guanylin-activated guanylate cyclase isoforms in human sweat glands.
Histochem J 32
: 725
–731, 2000[CrossRef][Medline]
Reinecke M, David I, Loffing-Cueni D, Ablinger P, Cetin Y, Kuhn M, Forssmann WG: Localization, expression and characterization of guanylin in the rat adrenal medulla.
Histochem Cell Biol 106
: 367
–374, 1996[Medline]
Jaleel M, London RM, Eber SL, Forte LR, Visweswariah SS: Expression of the receptor guanylyl cyclase C and its ligands in reproductive tissues of the rat: A potential role for a novel signaling pathway in the epididymis.
Biol Reprod 67
: 1975
–1980, 2002[Abstract/Free Full Text]
Steinbrecher KA, Tuohy TMF, Goss KH, Scott MC, Witte DP, Groden J, Cohen MB: Expression of guanylin is down regulated in mouse and human intestinal adenomas.
Bichem Biophys Res Commun 273
: 225
–230, 2000[CrossRef][Medline]
Cohen MB, Hawkins JA, Witte DP: Guanylin mRNA expression in human intestine and colorectal adenocarcinoma.
Lab Invest 78
: 101
–108, 1998
Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR: Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP.
Cancer Res 60
: 5151
–5157, 2000[Abstract/Free Full Text]
Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA: Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.
Proc Natl Acad Sci U S A 98
: 7846
–7851, 2001[Abstract/Free Full Text]
Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, Pamukcu R, Thompson WJ: Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.
J Pharmacol Exp Ther 299
: 583
–592, 2001[Abstract/Free Full Text]
Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB: Cyclic-GMP-dependent protein kinase inhibits the ras/mitogen-activated protein kinase pathway.
Mol Cell Biol 18
: 6983
–6994, 1998[Abstract/Free Full Text]
Steinbrecher KA, Wowk SA, Rudolph JA, Witte DP, Cohen MB: Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation.
Am J Pathol 161
: 2169
–2178, 2002[Abstract/Free Full Text]
Nakazato M, Yamaguchi H, Shiomi K, Date Y, Fujimoto S, Kangawa K, Matsuo H, Matsukura S: Identification of 10-kDa proguanylin as a major guanylin molecule in human intestine and plasma and its increase in renal insufficiency.
Biochem Biophys Res Commun 205
: 1966
–1975, 1994[CrossRef][Medline]
Nakazato M, Yamaguchi H, Kinoshita H, Kangawa K, Matsuo H, Chino N, Matsukura S: Identification of biologically active and inactive human uroguanylins in plasma and urine and their increases in renal insufficiency.
Biochem Biophys Res Commun 220
: 586
–593, 1996[CrossRef][Medline]
Kinoshita H, Fujimoto S, Fukae H, Yokota N, Hisanaga S, Nakazato M, Eto T: Plasma and urine levels of uroguanylin a new peptide in nephrotic syndrome.
Nephron 81
: 160
–164, 1999[CrossRef][Medline]
Fukae H, Kinoshita H, Fujimoto S, Nakazato M, Eto T: Plasma concentration of uroguanylin in patients on maintenance dialysis therapy.
Nephron 84
: 206
–210, 2000[CrossRef][Medline]
Kikuchi M, Fujimoto S, Fukae H, Kinoshita H, Kita T, Nakazato M, Eto T: Role of uroguanylin, a peptide with natriuretic activity, in rats with experimental nephrotic syndrome.
J Am Soc Nephrol 16
: 392
–397, 2005[Abstract/Free Full Text]
This article has been cited by other articles:
A. Sindic and E. Schlatter Mechanisms of action of uroguanylin and guanylin and their role in salt handling
Nephrol. Dial. Transplant.,
November 1, 2006;
21(11):
3007 - 3012.
[Full Text][PDF]
i
Top
Abstract
Introduction
) and UGN (
) mRNA along the intestinal tract. Adapted from reference (
